Neumora Therapeutics, Inc. (NMRA): Depreciation & Amortization
$208.0K
Year ended 2025-12-31
$47.0K
Trailing 12 months to 2026-06-30
-29.5%
3-year compound annual growth
| Period ended | Depreciation & Amortization | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $208.0K | -67.0% | 2026-03-30, From 2025-01-01 |
| 2024-12-31 | $631.0K | -5.5% | 2026-03-30, From 2024-01-01 |
| 2023-12-31 | $668.0K | +12.5% | 2025-03-03, From 2023-01-01 |
| 2022-12-31 | $594.0K | n/a | 2025-03-03, From 2022-01-01 |
Depreciation & Amortization at similar companies
| Company | Year ended | Depreciation & Amortization | Change YoY |
|---|---|---|---|
| Neumora Therapeutics, Inc. (NMRA) | 2025-12-31 | $208.0K | -67.0% |
| Vaxart, Inc. (VXRT) | 2025-12-31 | $8.58M | -3.1% |
| Instil Bio, Inc. (TIL) | 2025-12-31 | $534.0K | -85.2% |
| Caribou Biosciences, Inc. (CRBU) | 2025-12-31 | $3.65M | -7.2% |
| Sutro Biopharma, Inc. (STRO) | 2025-12-31 | $7.32M | +1.5% |
| SAB Biotherapeutics, Inc. (SABS) | 2025-12-31 | $2.99M | -36.4% |
| Compass Therapeutics, Inc. (CMPX) | 2025-12-31 | $276.0K | -53.1% |
| enGene Therapeutics Inc. (ENGN) | 2025-10-31 | $500.0K | +66.7% |
| Agenus Inc (AGEN) | 2025-12-31 | $10.00M | -25.1% |
Compare NMRA, VXRT, TIL, CRBU side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗